Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 14/20 | 0.55 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.51 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.51 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894140 | 0.83 | IL2 (0.53) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL2315236 | 0.83 | IL2 (0.50) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL2893273 | 0.83 | STIM1 (0.50) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL5554286 | 0.82 | IL2 (0.69) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL5029489 | 0.82 | IL2 (0.60) | IL2STIM1ORAI1MEN1KMT2A | |
| SCHEMBL3643758 | 0.80 | IL2 (0.49) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL2895062 | 0.80 | STIM1 (0.49) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL2892211 | 0.79 | IL2 (0.49) | IL2STIM1ORAI1ORAI2 | |
| SCHEMBL2891817 | 0.79 | STIM1 (0.53) | IL2STIM1ORAI1ORAI2MEN1 | |
| SCHEMBL15249605 | 0.79 | STIM1 (0.53) | IL2STIM1ORAI1ORAI2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8314130-B2 | Compounds inclunding substituted pyridines for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314130-B2 | Compounds inclunding substituted pyridines for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010039237-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130510-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885STIM1 924/4885ORAI1 729/4885 |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885STIM1 924/4885ORAI1 729/4885 |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885STIM1 924/4885ORAI1 729/4885 |
| US-20140107132-A1 | SUBSTITUTED PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, NOD1 | IL2 23/4885STIM1 934/4885ORAI1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.